Cytek Biosciences, Inc. (NASDAQ: CTKB) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.62 | Insider Own | 10.18% | Shs Outstand | 129.14M | Perf Week | 15.01% |
| Market Cap | 672.83M | Forward P/E | - | EPS next Y | -0.25 | Insider Trans | 0.00% | Shs Float | 118.26M | Perf Month | 11.56% |
| Enterprise Value | 433.83M | PEG | - | EPS next Q | -0.07 | Inst Own | - | Short Float | 4.17% | Perf Quarter | 30.90% |
| Income | -80.00M | P/S | 3.27 | EPS this Y | 44.62% | Inst Trans | - | Short Ratio | 3.74 | Perf Half Y | 20.05% |
| Sales | 206.00M | P/B | 2.09 | EPS next Y | 26.21% | ROA | -18.03% | Short Interest | 4.93M | Perf YTD | 3.17% |
| Book/sh | 2.49 | P/C | 2.57 | EPS next 5Y | - | ROE | -23.53% | 52W High | 6.18 -15.70% | Perf Year | 33.59% |
| Cash/sh | 2.03 | P/FCF | - | EPS past 3/5Y | - | ROIC | -11.90% | 52W Low | 3.28 58.84% | Perf 3Y | -27.84% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 7.02% 16.67% | Gross Margin | 53.23% | Volatility | 5.40% 4.94% | Perf 5Y | -80.23% |
| Dividend TTM | - | EV/Sales | 2.11 | EPS Y/Y TTM | -1244.90% | Oper. Margin | -21.60% | ATR (14) | 0.23 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.86 | Sales Y/Y TTM | 3.00% | Profit Margin | -38.98% | RSI (14) | 67.73 | Recom | 2.60 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.48 | EPS Q/Q | - | SMA20 | 10.62% | Beta | 1.17 | Target Price | 4.88 |
| Payout | 0.00% | Debt/Eq | 0.06 | Sales Q/Q | 4.35% | SMA50 | 13.29% | Rel Volume | 1.79 | Prev Close | 4.93 |
| Employees | 682 | LT Debt/Eq | 0.04 | Earnings | Nov 04 | SMA200 | 13.83% | Avg Volume | 1.25M | Price | 5.21 |
| IPO Date | Jul 23, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 46.43% 1.76% | Net Debt/EBITDA | 1.75 | Volume | 2,231,809 | Change | 5.68% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | Morgan Stanley | Equal Weight | $5.50 → $5.00 |
| May-13-26 | Reiterated | Stephens & Co. | Overweight | $4.75 |
| May-12-26 | Reiterated | Morgan Stanley | Equal Weight | $6.00 → $5.50 |
| Dec-01-25 | Reiterated | Morgan Stanley | Equal Weight | $6.00 |
| Mar-04-25 | Reiterated | Piper Sandler | Overweight | $8.50 → $8.00 |
| Feb-02-25 | Reiterated | Goldman Sachs | Buy | $4.50 → $5.25 |
| May-13-24 | Reiterated | Piper Sandler | Overweight | $16 → $8.50 |
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 206 | 201 | 200 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 97 | 97 | 89 | — | — | — | — | — | |
| Gross Profit | 110 | 104 | 111 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 118 | 108 | 92 | — | — | — | — | — | |
| Research and Development | 38 | 36 | 39 | — | — | — | — | — | |
| Other Operating Expense | -1 | 1 | 1 | — | — | — | — | — | |
| Operating Income | -44 | -40 | -21 | — | — | — | — | — | |
| Interest Expense | 1 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 5 | 11 | 15 | — | — | — | — | — | |
| Net Income Before Taxes | -41 | -30 | -6 | — | — | — | — | — | |
| Income Taxes | 40 | 37 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -80 | -67 | -6 | — | — | — | — | — | |
| Net Income From Continuing Operations | -80 | -67 | -6 | — | — | — | — | — | |
| Net Income | -80 | -67 | -6 | — | — | — | — | — | |
| EPS (Recurring) | -0.62 | -0.52 | -0.05 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.62 | -0.52 | -0.05 | — | — | — | — | — | |
| EPS (Diluted) | -0.62 | -0.52 | -0.05 | — | — | — | — | — | |
| EBITDA | -26 | -17 | 5 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.26 | 3.22 | 4.25 | — | — | — | — | — | |
| Gross Margin | 53.40 | 51.74 | 55.50 | — | — | — | — | — | |
| Operating Margin | -21.36 | -19.90 | -10.50 | — | — | — | — | — | |
| Net Margin | -38.83 | -33.33 | -3.00 | — | — | — | — | — | |
| Shares Outstanding | 129 | 128 | 131 | — | — | — | — | — | |
| Market Capitalization | 672 | 646 | 850 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Jiang Wenbin | PRESIDENT AND CEO | Aug 18 '26 | Option Exercise | 0.00 | 120,095 | 0 | 5,581,985 | Aug 20 |
| McCombe William D. | Chief Financial Officer | Aug 18 '26 | Option Exercise | 0.00 | 35,420 | 0 | 140,094 | Aug 20 |
| MUIR GLENN P | Director | Aug 18 '26 | Option Exercise | 0.00 | 3,086 | 0 | 3,086 | Aug 20 |
| Holder Michael | Director | Aug 18 '26 | Option Exercise | 0.00 | 2,181 | 0 | 62,875 | Aug 20 |
| Chin Richard | Director | Aug 18 '26 | Option Exercise | 0.00 | 6,107 | 0 | 28,499 | Aug 20 |
| Yan Ming | CHIEF TECHNOLOGY OFFICER | Aug 18 '26 | Option Exercise | 0.00 | 33,270 | 0 | 4,825,333 | Aug 20 |
| Ball Jack | Director | Jun 10 '26 | Option Exercise | 0.00 | 43,973 | 0 | 86,678 | Jun 12 |
| Imper Vera | Director | Jun 10 '26 | Option Exercise | 0.00 | 43,973 | 0 | 59,679 | Jun 12 |
| NEFF DEBORAH J | Director | Jun 10 '26 | Option Exercise | 0.00 | 43,973 | 0 | 59,679 | Jun 12 |
| Holder Michael | Director | Jun 10 '26 | Option Exercise | 0.00 | 43,973 | 0 | 60,694 | Jun 12 |
| Holder Michael | Director | May 18 '26 | Option Exercise | 0.00 | 1,454 | 0 | 16,721 | May 20 |
| Chin Richard | Director | May 18 '26 | Option Exercise | 0.00 | 6,107 | 0 | 22,392 | May 20 |
| Yan Ming | CHIEF TECHNOLOGY OFFICER | May 18 '26 | Option Exercise | 0.00 | 22,179 | 0 | 4,934,944 | May 20 |
| Busque Philippe | SVP, GLOBAL SALES AND SERVICES | May 18 '26 | Option Exercise | 0.00 | 10,464 | 0 | 44,890 | May 20 |
| Jiang Wenbin | PRESIDENT AND CEO | May 18 '26 | Option Exercise | 0.00 | 80,062 | 0 | 5,492,212 | May 20 |